As per Washington state guidance, masks are required regardless of vaccination status in all of our facilities. Please be aware that if you do not have a mask when you arrive we can provide one for you or reschedule your appointment. Exposure to someone that has tested positive for COVID requires a 14 day wait time regardless of vaccination status or a negative test before being seen in person. We appreciate your understanding!


Re-induction with Ustekinumab in Patients with Moderately to Severely Active Crohn's

  • Ustekinumab (STELARA) re-induction for patients with a loss of response being on a current dose of ustekinumab SC Q8W 90mg maintenance treatment. Need to have had at least 2 doses of SC 90mg of ustekinumab prior to enrollment.
  • Randomized 1:1 ratio to 1 of 2 intervention groups to receive either IV ustekinumab ~6 mg/kg and SC placebo or IV placebo and SC ustekinumab 90 mg in a blinded manner.
  • 16 weeks of treatment period followed by 2 follow up visits on WK24 and 36 or at 20weeks after last dose.

If you are interested in participating in clinical studies, please send an email to

17 Locations Focused on Serving Your Needs

Email us at